EU updates note on issuing duplicate drug marketing authorisations
This article was originally published in SRA
Executive Summary
The European Commission has issued a revised note on how it handles requests from pharmaceutical companies for duplicate marketing authorisations1,2. The revised note, among other things, attempts to clarify a misunderstanding by applicants of the term "true duplicate" in the March 2010 version of the document3,4.